A PYMNTS Company

Servia, Teva and others called out for generic-blocking

 |  July 30, 2012

French pharmaceutical company Servia as well as generic producers including Israel’s Teva received formal objections from the European Commission concerning alleged entry delay of the generic form of cardiovascular drug perindopril. By both buying up rare technology needed to create the drug and settling out of court with would-be generic producers, the Commission believes Servier abused its dominant market position by restricting competitive business. Similar pay-for-delay practices were denounced only a few days ago in the Commission’s objections issued to pharmaceutical powerhouse Lundbeck.

Full content: EU


Related content:  The EC Pharmaceutical Inquiry: Behind the Headlines, What is the Real Story on Innovation and Generic Competition in Pharmaceuticals?


Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.